Cargando…

Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease

Cholesterol guidelines typically prioritize primary prevention statin therapy on the basis of 10-year risk of cardiovascular disease. The advent of generic pricing may justify expansion of statin eligibility. Moreover, 10-year risk may not be the optimal approach for statin prioritization. We estima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohli-Lynch, Ciaran N., Lewsey, James, Boyd, Kathleen A., French, Dustin D., Jordan, Neil, Moran, Andrew E., Sattar, Naveed, Preiss, David, Briggs, Andrew H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022692/ https://www.ncbi.nlm.nih.gov/pubmed/35249370 http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057631

Ejemplares similares

Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
por: Shah, Aditya, et al.
Publicado: (2022)

Glycaemic Effects of Non-statin Lipid-Lowering Therapies
por: Collins, Patrick D., et al.
Publicado: (2016)

A dysglycaemic effect of statins in diabetes: relevance to clinical practice?
por: Swerdlow, Daniel I., et al.
Publicado: (2014)

Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial
por: Williams, Claire, et al.
Publicado: (2016)

Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
por: Williams, Claire, et al.
Publicado: (2016)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Estimating the healthcare cost of overweight and obesity in South Africa
por: Boachie, Micheal Kofi, et al.
Publicado: (2022)

Impact of China’s Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease
por: Wang, Miao, et al.
Publicado: (2020)

Hypertension in the South African public healthcare system: a cost-of-illness and burden of disease study
por: Kohli-Lynch, Ciaran N, et al.
Publicado: (2022)

Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
por: McCarey, David W, et al.
Publicado: (2005)

A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES”
por: Kohli-Lynch, Ciaran N, et al.
Publicado: (2021)

Diet in Stroke: Beyond Antiplatelets and Statins
por: James, Joe
Publicado: (2019)

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
por: Lee, Matthew M. Y., et al.
Publicado: (2019)

Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
por: Morofuji, Yoichi, et al.
Publicado: (2022)

Cost-Effectiveness of Masked Hypertension Screening and Treatment in US Adults With Suspected Masked Hypertension: A Simulation Study
por: Green, Matthew B, et al.
Publicado: (2022)

Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
por: Rankin, Naomi J, et al.
Publicado: (2016)

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
por: Sattar, Naveed, et al.
Publicado: (2016)

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017
por: Thalmann, Inna, et al.
Publicado: (2023)

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
por: Sattar, Naveed, et al.
Publicado: (2016)

Determinants of the Cost-Effectiveness of Statins
por: Morrison, Alan, et al.
Publicado: (2003)

Evaluating the Cost-Effectiveness of Statins
por: Hay, Joel W.
Publicado: (2004)

To JUPITER and beyond: Statins, inflammation, and primary prevention
por: Rao, Ajay D, et al.
Publicado: (2010)

New Drugs for Treating Dyslipidemia: Beyond Statins
por: Ahn, Chang Ho, et al.
Publicado: (2015)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011
por: Bouttell, Janet, et al.
Publicado: (2016)

Nurse led versus lay educators support for those with asthma in primary care: a costing study
por: Roberts, Nicola J, et al.
Publicado: (2012)

Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks?
por: Geue, Claudia, et al.
Publicado: (2015)

Beyond Statins: Emerging Evidence for HDL-Increasing Therapies and Diet in Treating Cardiovascular Disease
por: Farrer, Sterling
Publicado: (2018)

Anti-Inflammatory Effects of Statins Beyond Cholesterol Lowering
por: Joo, Seung-Jae
Publicado: (2012)

Challenges in Evaluating the Cost-Effectiveness of Statins
por: Ohsfeldt, Robert L.
Publicado: (2004)

When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins
por: Catalá-López, Ferrán, et al.
Publicado: (2013)

Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
por: Lloyd, Suzanne M., et al.
Publicado: (2013)

Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study
por: Brown, Rosemary, et al.
Publicado: (2021)

Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer
por: Boyd, Kathleen A, et al.
Publicado: (2015)

Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost‐effectiveness analysis
por: Boettiger, David C, et al.
Publicado: (2020)

The Cost-Effectiveness and Cost-Utility of Statin Drug for the Treatment of Patients with Cardiovascular Disease, A Systematic Review
por: Eisavi, Mahmoud, et al.
Publicado: (2021)

Costs of seasonal influenza vaccination in South Africa
por: Fraser, Heather, et al.
Publicado: (2022)

The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective
por: Rankin, Naomi J., et al.
Publicado: (2014)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hv2ve9250b1geu8ilrl0qi2q4p